Ar­ti­zan com­pletes mi­cro­bio­me starter pack­age with Brii deal, CSO hire and some mon­ey to dash for the clin­ic

Three years af­ter giv­ing a syn­op­sis of its mi­cro­bio­me play with some seed fund­ing from Ma­lin and Hat­teras Ven­ture Part­ners, Ar­ti­zan is rais­ing the cur­tain on their first act in in­flam­ma­to­ry bow­el dis­ease.

James Rosen Ar­ti­zan

Armed with $12 mil­lion in to­tal Se­ries A cash, a part­ner­ship with Chi­na’ Brii Bio and a new CSO hire, the New Haven, CT-based biotech is ready to hun­ker down for some pre­clin­i­cal work. Mean­while, CEO James Rosen tells me he will be get­ting to work rais­ing a Se­ries B in­tend­ed to fund clin­i­cal op­er­a­tions.

Yale im­muno­bi­ol­o­gy pro­fes­sor Richard Flavell and two col­lab­o­ra­tors pi­o­neered a new way to iden­ti­fy dis­ease-caus­ing bac­te­ria by scan­ning for an an­ti­body coat­ing called im­muno­glo­bin A (IgA). That was 2014.

“The coat­ing is our body’s at­tempt to neu­tral­ize the bac­te­ria,” Flavell said in 2014. “It binds to the bad bac­te­ria. We on­ly make these IgA re­spons­es to a lim­it­ed num­ber of or­gan­isms.”

It’s a more ef­fi­cient ap­proach than the tra­di­tion­al method of screen­ing for harm­ful bac­te­ria, which typ­i­cal­ly in­volves com­par­ing vast amounts of se­quenc­ing da­ta be­tween healthy and sick in­di­vid­u­als.

Richard Flavell Ar­ti­zan

Ze­ro­ing on the mi­crobes to tar­get, though, is on­ly the first step. Ar­ti­zan is look­ing in­to a num­ber of ways to get rid of them, from small mol­e­cules and an­ti­bod­ies to a ther­a­peu­tic vac­cine that could help the im­mune sys­tem mount a more po­tent at­tack.

Un­like some well-known play­ers in the mi­cro­bio­me field such as Seres and Finch, “we’re very specif­i­cal­ly not bugs as drugs,” Rosen said.

That opens up a broad range of po­ten­tial ap­pli­ca­tions for Ar­ti­zan’s plat­form, he said, as man­i­fest­ed in Brii’s de­ci­sion to col­lab­o­rate on up to three pro­grams. Brii — a $260 mil­lion pow­er biotech play spear­head­ed by GSK vet Zhi Hong — will pick up Chi­na de­vel­op­ment and com­mer­cial­iza­tion once Ar­ti­zan pro­duces proof-of-con­cept in the next cou­ple of years.

The deal comes with an undis­closed set of up­front, mile­stone and roy­al­ty pay­ments in ad­di­tion to a ven­ture in­vest­ment, plac­ing Brii in a syn­di­cate that in­cludes John­son & John­son De­vel­op­ment In­no­va­tion – JJDC, Os­age Uni­ver­si­ty Part­ners and Elm Street Ven­tures.

Paul Miller Syn­log­ic

Co­or­di­nat­ing the whole re­search ef­fort from dis­cov­ery to drug de­vel­op­ment and join­ing the 11-per­son team would be Paul Miller, the new chief sci­en­tif­ic of­fi­cer. Miller, a sea­soned ex­ec groomed in As­traZeneca and Pfiz­er, jumps from Syn­log­ic, which spe­cial­izes in reengi­neer­ing bac­te­ria in­to ther­a­peu­tics.

“It’s an ex­cit­ing time to join Ar­ti­zan’s ef­forts to ad­dress the un­met treat­ment need in IBD, a dis­ease that af­fects more than 1.6 mil­lion Amer­i­cans,” Miller said in a state­ment.

The Avance Clinical leadership team: CEO Yvonne Lungershausen, Sandrien Louwaars - Director Business Development Operations, Gabriel Kremmidiotis - Chief Scientific Officer, Ben Edwards - Chief Strategy Officer

How Aus­tralia De­liv­ers Rapid Start-up and 43.5% Re­bate for Ear­ly Phase On­col­o­gy Tri­als

About Avance Clinical

Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services to the local and international drug development industry for 20 years. They specialise in working with biotech companies to execute Phase 1 and Phase 2 clinical trials to deliver high-quality outcomes fit for global regulatory standards.

As oncology sponsors look internationally to speed-up trials after unprecedented COVID-19 suspensions and delays, Australia, which has led the world in minimizing the pandemic’s impact, stands out as an attractive destination for early phase trials. This in combination with the streamlined regulatory system and the financial benefits including a very favourable exchange rate and the R & D cash rebate makes Australia the perfect location for accelerating biotech clinical programs.

As­traZeneca trum­pets the 'mo­men­tous' da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

David Chang, Allogene CEO (Jeff Rumans)

Head­ed to PhII: Al­lo­gene CEO David Chang com­pletes a pos­i­tive ear­ly snap­shot of their off-the-shelf CAR-T pi­o­neer

Allogene CEO David Chang has completed the upbeat first portrait of the biotech’s off-the-shelf CAR-T contender ALLO-501 at virtual ASCO today, keeping all eyes on a drug that will now try to go on to replace the first-wave personalized pioneers he helped create.

The overall response rate outlined in Allogene’s abstract for treatment-resistant patients with non-Hodgkin lymphoma slipped a little from the leadup, but if you narrow the patient profile to treatment-naïve patients — removing the 3 who had previous CAR-T therapy who didn’t respond, leaving 16 — the ORR lands at 75% with a 44% complete response rate. And 9 of the 12 responders remained in response at the data cutoff, offering a glimpse on durability that still has a long way to go before it can be completely nailed down.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Sanofi brings in 4 new ex­ec­u­tives in con­tin­ued shake-up, as vac­cines and con­sumer health chief head out the door

In the middle of Sanofi’s multi-pronged race to develop a Covid-19 vaccine, David Loew, the head of their sprawling vaccines unit, is leaving – part of the final flurry of moves in the French giant’ months-long corporate shuffle that will give them new-look leadership under new CEO Paul Hudson.

The company also said today that Alan Main, the head of their consumer healthcare unit, is out, and they named 4 executives to fill new or newly vacated positions, 3 of whom come from both outside both Sanofi and from Pharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca’s $7B ADC suc­ceeds where Roche failed, im­prov­ing sur­vival in gas­tric can­cer

Another day, another win for Enhertu.

The antibody-drug conjugate AstraZeneca promised up-to $7 billion to partner on has had a quite a few months, beginning with splashy results in a Phase II breast cancer trial, a rapid approval and, earlier this month, breakthrough designations in both non-small cell lung cancer and gastric cancer.

Now, at ASCO, the British pharma and their Japanese partner, Daiichi Sankyo, have shown off the data that led to the gastric cancer designation, which they’ll take back to the FDA. In a pivotal, 187-person Phase II trial, Enhertu shrunk tumors in 42.9% of third-line patients with HER2-positive stomach cancer, compared with 12.5% in a control arm where doctors prescribed their choice of therapy. Progression-free survival was 5.4 months for Enhertu compared to 3.5 months for the control.

Once a gem, now just a rock, Take­da punts PhI­II IBD drug as ri­vals mus­cle ahead

Back in 2016, when then-Shire CEO Flemming Ørnskov picked up a promising clinical-stage IBD drug from Pfizer, the Boston-based biotech dubbed it SHP647 and moved it into the gem section of the pipeline, with rosy expectations of registration-worthy Phase III data ahead.

This was a drug that the EC wanted Takeda to commit to selling off before it gave their blessing to its acquisition of Shire, to settle some deep-seated concerns revolving around the potential market overlap with their blockbuster rival Entyvio. And Takeda, which took on a heavy debt load to buy Shire, clearly wanted the cash to pay down debt.

Sier­ra On­col­o­gy brings on for­mer Aim­mune CEO to the helm; Flag­ship woos ex-No­var­tis ex­ec Fab­rice Chouraqui

Momelotinib-focused Sierra Oncology, which launched a Phase III trial in November for myelofibrosis patients, has made Stephen Dilly its president and CEO, effective June 1. Dilly was previously the CEO at Aimmune from 2014 until what was billed as his retirement in 2018, but now he’s back at the helm of another company and is also a member of Sierra’s board of directors. Additionally, the seasoned vet has held posts at Genentech, Chiron and GSK.